Novo Nordisk has hauled rival Eli Lilly into federal court in New Jersey, accusing the Indianapolis drug giant of juicing an advertising campaign to make its blockbuster weight-loss drugs look stronger than they are head-to-head. In a complaint filed Tuesday, Novo says Lilly stacked the deck by spotlighting Lilly’s best high-dose numbers against older, lower-dose data for Novo’s shots, while steering clear of newer, higher-dose versions that narrow the gap. Novo wants a judge to yank the ads and, if Lilly will not pull them on its own, to force a corrective campaign.
As reported by Reuters, the case landed in U.S. District Court in New Jersey and accuses Lilly of violating federal and state false-advertising and unfair-competition laws, including the Lanham Act. Novo is targeting ads for Lilly’s obesity drug Zepbound and its diabetes treatment Mounjaro and is asking the court to pull those spots and order Lilly to run corrective ads.
What Novo Is Accusing Lilly Of
In the lawsuit, Novo says Lilly compared the highest approved doses of its drugs with lower doses of Novo’s Wegovy and Ozempic, a matchup that, in Novo’s view, was built to flatter Lilly. The complaint also says Lilly left out newer, higher-dose Novo formulations that would tighten the apparent spread.
John Kuckelman, Novo’s general counsel, told Reuters that Lilly “did not respond to the cease-and-desist letter and inserted an inadequate disclaimer into the advertisements.” Novo says that if the ads are not removed, it will move for a preliminary injunction to stop the campaign early in the case.
Numbers At Issue
The flash point is a simple but potent comparison. Novo says Lilly ran with a claim that Zepbound delivered roughly 50 pounds of weight loss against about 33 pounds for Wegovy, a split Novo calls misleading.
The complaint points to late-stage trial data that make the gap look smaller. Zepbound’s SURMOUNT-1 study showed mean weight losses near 48 pounds at the highest dose, according to Drugs.com. Novo’s Wegovy STEP trials, summarized on DailyMed, reported average losses in the mid-30s, which still trails Lilly but not by as much as the ad figures suggest.
Where This Fits In The GLP-1 Fight
The case drops into an already crowded battlefield over how GLP-1 drugs are sold, described and copied. Novo’s filing is the latest in a string of legal and regulatory moves taking aim at claims around these medicines and at cheaper copycat versions sold by telehealth outfits and compounding pharmacies. Bloomberg Law and other outlets have tracked lawsuits and warning letters from the FDA that call out misleading promises and promotion of products that are not FDA approved.
Legal Implications
Novo is leaning hard on the Lanham Act, the federal law that lets one company sue another over allegedly false or misleading ads. Under that statute, a plaintiff has to show a materially false statement in commercial advertising that deceived or is likely to deceive consumers and that caused a commercial injury. The text of the law is posted by Cornell Law School.
Legal analysis, including commentary from LegalClarity, notes that courts often want more than hurt feelings when they are asked to order corrective ads. Judges typically look for evidence that the disputed campaign actually moved customers or dented a rival’s reputation before granting that kind of extraordinary relief.
What To Watch Next
In the short term, the action is likely to center on motion practice: whether Novo gets the preliminary injunction it has threatened to seek and whether Lilly fights over venue or timing. How quickly the judge moves could determine whether these ads stay on the air while the case plays out.
The stakes are being watched especially closely in Indianapolis, where Lilly’s headquarters and a wave of recent manufacturing projects have turned the company into a major local economic engine. One recent expansion poured an extra $4.5 billion into a new drug hub in Lebanon, Indiana, as reported in Lilly's extra $4.5 billion Lebanon bet. For a company investing that heavily at home, the outcome of a national ad fight over its star drugs is not just about bragging rights, it is about protecting a core business line.
